Greetings and Happy Holidays!

Thank you for following and being part of Anviron's journey this year. Our team had an incredible 2025 and we are thrilled at our progress developing a breakthrough family of cancer drugs. Previously, our lead experimental drug candidate, ANV221 (previously APPB), was awarded FDA orphan drug designation for the treatment of Pancreatic Cancer based on its superiority over chemotherapy drug, Gemcitabine, and we have expanded our disease indications with compelling results in drug-resistant breast cancers. We performed extensive in vivo safety and efficacy studies this year and the results were nothing less than astounding!

We are thrilled to share that ANV221 showed vast superiority over the preferred HER2-positive breast cancer drug (trastuzumab) in every breast cancer we tested. Importantly, when trastuzumab stops working, ANV221 treatment re-sensitizes the cancer to trastuzumab by up to 90% resulting in a powerful combination effect.

Our team made even more exciting discoveries in our safety studies. We previously found that a daily dose of ANV221 at 10mg/kg in vivo eliminated all pancreatic tumors in just two weeks. Competing drugs against our target are lethal with a single dose of just 1/10 this amount. This summer, we treated our animals at 10mg/kg every day for over 45 days, with NO OBSERVED SIGNS OF TOXICITY. We are one step closer to ending two horrific subsets of cancer.

This summer, we welcomed Brian Boynton MD as our Chief Medical Officer. Dr. Boynton brings a wealth of clinical experience as a surgeon treating diseases of the head and neck, including cancer, for the past decade and will be a strong addition to our already stellar drug development team.

The discovery that cancer cells display different glycoproteins—sugar-modified proteins—on their surface began a race to identify these cancer-associated structures and target them with the next generation of therapeutics. A race that Anviron finds itself in the POLE POSITION, with researchers all over the world citing our compounds in peer-reviewed, published science journals.

> *"Further exploration of the anti-cancer effects of (Anviron's) APPB is warranted." – Yang, Song, et al, J. Clinical Onc (2023)*

This summer, Anviron's research team, led by our head of Science, Dr. Michio Kurosu, summarized his findings in his article, *"DPAGT1 – Perspective as an Anticancer Drug Target",* published in Molecules, a well-regarded, peer-reviewed science journal: https://doi.org/10.3390/molecules30204049

> *"Remarkably, this intervention (DPAGT1 inhibition) re-sensitized trastuzumab-resistant tumors, leading to profound tumor regression in the trastuzumab resistant HER2+ breast cancer models." – Kurosu et al*

Our team is building powerful AI drug safety tools to accelerate FDA-mandated studies and if all goes well, we expect to enroll our first patient in the second half of 2026. According to JAMA, the average pharmaceutical company will have spent nearly $600m before reaching our stage. Our plan is to reach clinical stage with less than $1m, a capital efficiency virtually unheard of in pharmaceutical development.

The positive developments continue: We were recently notified by European and Hong Kong, China patent offices that our patent application for ANV221 will be awarded in March 2026 for the treatment of several solid tumor cancers. This adds to our three existing US and Japanese patents as well as our several continuation patents that expanded our indications to include several, difficult to treat solid tumor cancers.

If you would like to be involved in our incredible journey, we are recruiting pancreatic and breast cancer patient advocates and welcome input from key opinion leaders in these fields. We are aggressively seeking research expertise in the oncology fields, regulatory guidance, grant writing, and foundational support.

Happy Holidays from the Anviron Team!

Very best regards,

The Anviron Team